Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions

Indian Journal of Endocrinology and Metabolism

Volumn 19, Issue 3, 2015, Pages 426-429

  Kalra, Sanjay ^a   Gupta, Yashdeep ^b   Patil, Shiva ^c  

^a Bharti Hospital and BRIDE ^*  (India)

^b GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

^c Boehringer Ingelheim Pvt Ltd   (India)

Author keywords

Beta cell; canagliflozin; dapagliflozin; diabetes; empagliflozin; glucagon; insulin

Indexed keywords

EID: 84981190782     PISSN: 22308210     EISSN: 22309500     Source Type: Journal    
DOI: 10.4103/2230-8210.152793     Document Type: Article

References (20)

1. Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 2013;1:140-51.
2. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499-508.
3. Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124:509-14.
4. Unger RH. Glucoregulatory hormones in health and disease. A teleologic model. Diabetes 1966;15:500-6.
5. Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95.
6. Haidar A, Legault L, Messier V, Mitre TM, Leroux C, Rabasa-Lhoret R. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: An open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol 2015;3:17-26.
7. Tsuchiyama N, Takamura T, Ando H, Sakurai M, Shimizu A, Kato K, et al. Possible role of alpha-cell insulin resistance in exaggerated glucagon responses to arginine in type 2 diabetes. Diabetes Care 2007;30:2583-7.
8. Parrilla R, Goodman MN, Toews CJ. Effect of glucagon: Insulin ratios on hepatic metabolism. Diabetes 1974;23:725-31.
9. Wilmore DW, Lindsey CA, Moyland JA, Faloona GR, Pruitt BA, Unger RH. Hyperglucagonaemia after burns. Lancet 1974;1:73-5.
10. Kuhl C, Holst JJ. Plasma glucagon and the insulin: Glucagon ratio in gestational diabetes. Diabetes 1976;25:16-23.
11. Unger RH. Glucagon and the insulin: Glucagon ratio in diabetes and other catabolic illnesses. Diabetes 1971;20:834-8.
12. Bonner C. The Glucose Transporter SGLT 2 Is Expressed in Human Pancreatic Alpha Cells and Is Required for Proper Control of Glucagon Secretion in Type 2 Diabetes. Oral presentation in 74th Scientific Meet of American Diabetes Association; 2014.
13. Bonner C. Glucose Transporter SGLT2 Inhibition Triggers Glucagon Secretion in Alpha Cells. Poster Presented at EASD Meeting; 2014. ePoster #609.
14. Murray RK, Bender DA, Botham KM, Kennelly PJ, Rodwell VW, Weil PA, editors. Chapter Oxidation of fatty acids: Ketogenesis Harper's Illustrated Biochemistry. 28th ed. The McGraw Hill Companies; 2009.
15. Murray RK, Bender DA, Botham KM, Kennelly PJ, Rodwell VW, Weil PA, editors. Biosynthesis of fatty acids and eicosanoids. Harper's Illustrated Biochemistry. 28th ed. The McGraw Hill Companies; 2009.
16. Bollheimer LC, Landauer HC, Troll S, Schweimer J, Wrede CE, Schölmerich J, et al. Stimulatory short-term effects of free fatty acids on glucagon secretion at low to normal glucose concentrations. Metabolism 2004;53:1443-8.
17. Lehtihet M, Welsh N, Berggren PO, Cook GA, Sjoholm A. Glibenclamide inhibits islet carnitine palmitoyltransferase 1 activity, leading to PKC-dependent insulin exocytosis. Am J Physiol Endocrinol Metab 2003;285:E438-46.
18. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74.
19. Kalra S, Unnikrishnan AG, Sahay R. Metformin and the promise of geroprotection. Indian J Endocrinol Metab 2012;16:496-8.
20. Verspohl EJ. Novel pharmacological approaches to the treatment of type 2 diabetes. Pharmacol Rev 2012;64:188-237.